Alexion Rare Disease Launches Off To Slow Start
This article was originally published in Scrip
Executive Summary
You may also be interested in...
Alexion's Managed Access Agreement Only Partially Quashes Strensiq Cost Concerns
Alexion has only managed to convince NICE to recommend Strensiq for treatment in a limited patient population with pediatric-onset hypophosphatasia. The news is a step forward after NICE initially declined the drug altogether, but the new recommendations highlight the difficulties companies face when trying to justify high orphan drug prices.
Pfizer's Medivation Buyout: One-Off Deal Or Start Of A Biopharma Spending Spree?
More and larger M&A deals could boost public biopharmaceutical companies, so investors will watch closely to see if Pfizer's $14bn Medivation acquisition kicks off a widespread spending spree. Speculation about who'll be bought next is in full swing.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.